Gyre Therapeutics Highlights Evofem's SOLOSEC® Patent Boosting Women's Health Market Position
- Evofem Biosciences secured a new patent for SOLOSEC®, extending protections until December 2041.
- The patent enhances SOLOSEC's market position as a unique single-dose treatment for trichomoniasis and bacterial vaginosis.
- Evofem is conducting a Phase 4 trial to evaluate SOLOSEC's effectiveness and cost-efficiency compared to traditional treatments.
Evofem Biosciences Strengthens Market Position with New Patent for SOLOSEC®
Evofem Biosciences, Inc. recently announces the issuance of a new U.S. patent that significantly extends the intellectual property protections for its innovative product, SOLOSEC® (secnidazole) 2 g oral granules, into December 2041. This patent, designated as Patent No. 12,280,037, is now part of the FDA's Orange Book and covers a wide array of claims, including the method, pharmaceutical composition, and the use of SOLOSEC for the treatment of trichomoniasis—a commonly encountered sexually transmitted infection that sees around 6.9 million new cases annually in the United States. This extension solidifies Evofem's competitive edge in the market, particularly since SOLOSEC is recognized as the first and only FDA-approved single-dose oral treatment for both bacterial vaginosis (BV) and trichomoniasis.
CEO Saundra Pelletier emphasizes the importance of this patent for the company’s growth strategy, highlighting that it allows Evofem to build a stronger brand presence for SOLOSEC while also delivering value to prescribers and patients. The patent is expected to play a crucial role in the company's ongoing efforts to expand its market reach and solidify its reputation in the women’s sexual and reproductive health sector. Additionally, Evofem is currently recruiting participants for a Phase 4 clinical trial funded by the NIH, which aims to evaluate the effectiveness and cost-efficiency of SOLOSEC compared to the traditional multi-day treatment regimen with metronidazole. The hypothesis is that SOLOSEC will not only reduce the rate of repeat infections but will also prove to be more economically viable over time, despite its higher upfront cost.
The advancements surrounding SOLOSEC come at a critical time when the demand for innovative solutions in women's health is more pressing than ever. With the new patent and ongoing clinical studies, Evofem is well-positioned to address unmet needs in this area, potentially transforming the treatment landscape for conditions that affect millions of women. As the company moves forward, the focus remains on providing effective and simplified treatment options that improve patient outcomes and promote better health in the community.
In other developments within the biotechnology sector, Quintara Biosciences launches a new service called Whole Plasmid Sequencing – Express (WPS-Express), aimed at enhancing research efficiency. This ultra-fast, flat-rate sequencing service allows researchers to obtain complete plasmid sequences with a remarkable overnight turnaround time, addressing the growing demands of modern scientific inquiries in molecular cloning and synthetic biology.
Meanwhile, Anixa Biosciences announces a significant milestone with the issuance of a Notice of Allowance for a new patent concerning its breast cancer vaccine technology from the Chinese National Intellectual Property Administration (CNIPA). This patent not only strengthens Anixa's global patent portfolio but also highlights the innovative approach the company is taking towards addressing breast cancer treatment and prevention, especially as the incidence of this disease continues to rise globally.